Cellectis Launches Ectycell Subsidiary Dedicated to Stem Cells Applications

05-Oct-2009 - France

Cellectis S.A. has announced the incorporation of Ectycell, a subsidiary dedicated to the biomedical uses of stem cells. The initial applications developed are (i) tools for generating induced pluripotent stem cells from adult cells, (ii) robust, reproducible differentiation of stem cells and (iii) the constitution of cell libraries for testing drug candidates.

"Cellectis' core technologies will have a major impact on the stem cell field", stated David Sourdive, CEO of Ectycell. "We are tackling important issues here, such as reducing the high attrition rate in drug development by using early-stage assays that better predict a molecule's effect on the organism as a whole or on a genetically diverse population. We also may have the opportunity to open new paths for regenerative medecine - especially for pathologies like Alzheimer's and Parkinson's diseases".

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance